drugset / Trial / NCT00298285

ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement

NCT00298285

Phase 4 Completed 100 enrolled The Cleveland Clinic
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary aim is to determine the rate of major bleeding and blood clots when using enoxaparin as a bridge to oral blood thinning medication in patients who have undergone mechanical valve replacement.

Timeline

Start
Primary completion
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified Other

Indications

No indication recorded.